Article Details

China's genome editing startup EdiGene nets $62m in Series B+ round

Retrieved on: 2021-04-22 03:00:00

Tags for this article:

Click the tags to see associated articles and topics

China's genome editing startup EdiGene nets $62m in Series B+ round. View article details on hiswai:

Excerpt

... Capital, Lilly Asia Venture, 3H Health Investment, Huagai Capital, Sequoia Capital China, Alwin Capital, and Kunlun Capital re-upped in the deal.

Article found on: www.dealstreetasia.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up